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Abstract. BPD 28D (O2 dependency at 28 days of life) and BPD 36W (O2 dependency at 36 wks post-menstrual age) are
diseases of prematurely born infants exposed to mechanical ventilation and/or oxygen supplementation. In order to determine
whether genetic variants of surfactant proteins (SPs-A, B, C, and D) and SP-B-linked microsatellite markers are risk factors
in BPD, we performed a family based association study using a Greek study group of 71 neonates (<30 wks gestational age)
from 60 families with, 52 BPD 28D and 19 BPD 36W, affected infants. Genotyping was performed using newly designed
pyrosequencing assays and previously published methods. Associations between genetic variants of SPs and BPD subgroups were
determined using Transmission Disequilibrium Test (TDT) and Family Based Association Test (FBAT). Significant associations
(p  0.01) were observed for alleles of SP-B and SP-B-linked microsatellite markers, and haplotypes of SP-A, SP-D, and
SP-B. Specifically, allele B-18 C associated with susceptibility in BPD 36W. Microsatellite marker AAGG 6 associated with
susceptibility in BPD 28D/36W group. Haplotype analysis revealed ten susceptibility and one protective haplotypes for SP-B
and SP-B-linked microsatellite markers and two SP-A-SP-D protective haplotypes. The data indicate that SP loci are linked to
BPD. Studies in different study groups and/or of larger sample size are warranted to confirm these observations and delineate
genetic background of BPD subgroups.
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1. Introduction
Bronchopulmonary dysplasia (BPD) is the most
common cause of morbidity in prematurely born infants
who require prolonged mechanical ventilation [30].
BPD is almost exclusively a disease of severely prema-
ture (24–28 weeks of gestation), extremely low birth
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weight (ELBW, less than 1000 gr) infants who have
been exposed to high airway pressures and/or high in-
spired oxygen concentrations [26,38]. Despite the dra-
matic improvements in neonatal care the incidence of
BPD is on the rise due to the increased survival of
the smallest infants [2]. BPD infants have structurally
and biochemically immature lungs, the development of
which is disrupted due to a number of harmful stim-
uli [29,30]. These processes lead to an impaired alve-
olar and capillary growth and overall an abnormal lung
structural development that can have long term conse-
quences [3,14].
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It has been noted that genetic factors may contribute
to BPD [27]. Gene expression profile studies of an
animal model of BPD implicated several genes in the
pathogenesis of this disease [57]. Candidate gene and
linkage analysis are approaches used to identify genes
associated with multifactorial diseases such as BPD.
Although there have been very few studies on the ge-
netic background of BPD in humans, preliminary re-
ports have shown an association between BPD and sur-
factant proteins [39,62]. A recent case control study
has demonstrated that the frequency of SP-B intron 4
deletion variant alleles is increased in BPD versus con-
trol infants even when essential external confounding
factors, such as birth order, are included in the analy-
sis [50].
Surfactant proteins (SPs) are good candidate genes
of neonatal disease due to their role in lung devel-
opment and maturation [4,15,19,63]. These proteins
are components of pulmonary surfactant, a lipoprotein
complex necessary for lung function [15]. Surfactant
protein (SP-) B and SP-C play important roles in sur-
factant structure and surface tension lowering proper-
ties [61], while SP-A and SP-D play a role in local host
defense and regulation of inflammatory processes in
the lung [6,46,65]. Deficiency of surfactant can result
in Respiratory Distress Syndrome (RDS) in premature
infants. The lungs of these infants have been identified
to have low SP levels [9,10]. Association of genetic
variants of SP-A and SP-B with RDS has been demon-
strated by both case control and family-based linkage
studies [16–19,21,22,41,42]. Since BPD is commonly
preceded by RDS, overlapping underlying mechanisms
regulated by the same genetic factors may play a role
in the etiology of both diseases.
In this report, we sought to perform a family based
association study in order to identify whether al-
leles and/or haplotypes of surfactant protein genes
(SP-A, SP-B, SP-C, and SP-D) and SP-B-linked mi-
crosatellite markers are susceptibility or protective fac-
tors in BPD. Associations between single nucleotide
polymorphisms (SNPs) of surfactant proteins and
BPD were tested using Transmission Disequilibrium
Test (TDT) [55] and Family Based Association Test
(FBAT) [24,34,47]. The extended TDT (ETDT) [7,
52] and multi-allelic FBAT [25] were used to test for
markers with multiple alleles.
To accelerate genotype analysis necessary for this
study, we adapted our previously described PCR-
cRFLP method [11] to the recently introduced pyrose-
quencing method. Pyrosequencing is a primer exten-
sion based method that has been used for a variety
Table 1
Characteristics of population used in the study
Number of children BPD at 28 days BPD at 36 weeks
per family
1 35=Y + 6* 11 + 4*
2 4 2
3 1 0
Total number of families 46 17
*These families have a second child that was diagnosed with either
RDS or the other form of BPD
=YTwo families have only mothers and no fathers, all others have both
mother and father.
One family has only mother and no father, all others have both
mother and father.
of biological applications, including SNP genotyping,
SNP discovery, haplotyping, insertion/deletion studies,
methylation studies and allele frequency studies [12,
49]. This flexible, high-throughputmethod of genotyp-
ing improves on our previously published PCR-cRFLP
method [11] by reducing the time and effort necessary
for data acquisition.
2. Materials and methods
2.1. Study population
The study population consisted of 60 families from
Greece with 71 affected infants, as outlined in Ta-
ble 1. All infants required supplemental oxygen at 28
days of life. All infants were intubated and required
FiO2 >0.30 on day 1 of life. Sixty four of them had
RDS and were treated with surfactant. Out of 71 af-
fected infants, 52 fulfilled the criteria for BPD at 28
days as described by Bancalari et al. [1]. All infants
with BPD at the 28 days category met the Bancalari
et al. criteria of supplemental oxygen requirement 28
days after birth, persistent abnormalities in the chest
radiograph, and tachypnea in the presence of rales or
retractions. This subgroup of infants is referred to here
as BPD 28D. Nineteen infants went on to be oxygen
dependent at 36 weeks of post-menstrual age [53]. This
subgroup of infants is referred to here as BPD 36W.
When the two subgroups are combined for analysis,
they are referred to as BPD 28D/36W. The study pro-
tocol was approved by institutional committees of the
participating hospitals and written parental consent ob-
tained from each family.
2.2. Isolation of DNA
DNA was extracted from 200 µl of blood using the
QIAamp DNA Blood Midi kit (Qiagen, Valencia, CA)
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Sequence to analyze                                            
AA223: G/TCTCTTTTCCCCGA
Dispensation order: ATGACTCTCGA
Sequence to analyze                                           
AA140: CTA/GGAGAAGACCTT
Dispensation order: CTCGACGAGAGACT
Sequence to analyze                                             
AA140: CTA/GGAGAAGACCTT AA223: 
G/TCTCTTTTCCCCGA Dispensation 
order: ATGTCTAGTAGCTCG
Panel A Panel B Panel C
I)
II)
III)
Fig. 1. Simplex and multiplex pyrosequencing for SP-A (AA140 and AA223): Expected patterns from simplex pyrosequencing analysis (panels
A and B) and multiplex analysis (panel C) of two SNPs (AA140 and AA223) are presented as histograms. There are three possible patterns of
nucleotide distribution in simplex pyrosequencing for each SNP (panel A for AA140 SNP; panel B for AA223 SNP), while nine combinations
are possible for multiplex pyrosequencing (only three are represented in panel C). The positions of the SNPs of interest are highlighted in yellow
and outlined with a dashed line. Panel B: The sequencing primer for the AA223 SNP (G/T) is right in front of the SNP, and this makes it the
most straight forward type of sequencing reaction (as compared to that in panel A). Since the AA223 sequence (G/TCTCTTTTCCCC, Panel B),
does not contain an A nucleotide, this can serve as negative control. The nucleotides serving as negative controls are identified by an arrow at the
bottom of each panel. Whenever possible, the negative control nucleotide is dispensed first. For example, in panel B, the nucleotide dispensation
order is as follows: the negative control (A) is followed by a T and then a G nucleotide (constituting the SNP). These are followed by another
negative control A nucleotide (arrow). The dispensation order then continues to sequence through a short segment of the surrounding DNA
sequence, in this case CTCTTTTCCCC (panel B), in order to ensure that the SNP analyzed is within the DNA segment of interest. Note the
difference in peak height when a single T or C is dispensed versus four Ts or four Cs are dispensed in sequence. Panel portions I and III depict
homozygous SNP patterns (G and T, respectively in panel B), while the II portion of each panel depicts a heterozygous SNP pattern (G/T in panel
B). Panel A: For AA140 SNP, the sequencing primer is not right in front of the SNP site, as it is for the AA223 SNP (panel B). In this case two
nucleotides (C and T) precede the SNP (A/G). Therefore, in the sequencing reaction, a G nucleotide (negative control, arrow) is dispensed. This
is followed by dispensation of a C and a T that sequence the CT preceding the A/G SNP. Due to the fact that another G nucleotide is immediately
adjacent to the A/G SNP, the specific SNP signal for G overlaps with the flanking G, as represented by the double peak height in panel A.I. A
negative control C nucleotide (arrow) is dispensed following the A/GG sequence, and sequencing of surrounding bases continues as in panel
B. Panel C: Both SNPs (AA140 and AA223) are sequenced at once. Due to the dispensation order set-up AA223 SNP is sequenced first (red
bars), as in panel B, followed by a negative control T. The dispensation of the following C and T nucleotides, sequences through both AA223 and
AA140 sequence at once (block arrow, red and blue bars overlap). Dispensation of the A and G nucleotides, sequences through the AA140 SNP
site (blue bars). This SNP site is followed by a negative control (T nucleotide, arrow). The remaining stretch of nucleotides is the surrounding
sequence for both AA140 (AG, blue bar) and AA223 (CTTTTCCCCG, red bar).
according to manufacturer’s instructions. DNA was
eluted in the final step using 200 µl of DNase free dH2O
(Ambion). Upon extraction DNA was stored at−20◦C
until further handling.
2.3. Pyrosequencing: General considerations, primer
design, template preparation and plate set-up
a) Background: Pyrosequencing is a primer based
DNA sequencing method, where DNA synthesis is
monitored by four different enzymes and detected
through luminescence in the form of a light pulse. It
is performed on single stranded DNA templates pro-
duced by PCR and separation of the biotinylated sin-
gle strands (see below). Then a sequencing primer hy-
bridization to the complementary bases on the single
stranded PCR template initiates nucleotide incorpora-
tion by DNA polymerase. As each new nucleotide is
incorporated, a pyrophosphate (PPi) group is released
in an equimolar proportion to the amount of the incor-
porated nucleotide. This pyrophosphate is converted to
ATP by the ATP sulfurylase, which in turn drives the
conversion of luciferin to oxyluciferin by luciferase.
The light produced as a result of this reaction is detected
by a charge-coupled device (CCD) camera. Each light
signal is proportional to the number of nucleotides in-
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Table 2
SNPs of surfactant protein genes studied
SP-A1 SP-A2 micosatellite markers SP-B SP-C SP-D
AA19(C/T) AA9(A/C) D2S388 B-18(A/C) CA138(A/C) DA11(C/T)
AA50(C/G) AA91(C/G) D2S2232 B1013(A/C) CA186(A/G) DA160(A/G)
AA62(A/G) AA140(C/T) AAGG B1580(C/T)
AA133(A/G) AA223(A/C) B9306(A/G)
AA219(C/T)
SP-A1, SP-A2, SP-C, and SP-D SNP positions are based on the amino acid number of the amino acid
sequence deduced from the cDNA (for SP-D the amino acid numbering starts after cleavage of signal
peptide, while for SP-A and SP-C starts prior to the signal peptide cleavage). The first letter denotes the
gene (A for SP-A, C for SP-C, D for SP-D), and the second letter (A) stands for amino acid. For SP-B SNPs,
the numbers refer to the nucleotide position of the polymorphism [36]. The polymorphic variant of each
SNP is given in parenthesis. For SP-A, haplotypes consisting of SNPs within the coding sequence that may
or may not change the encoded amino acid are denoted as 6A or 1A for SP-A1 and SP-A2, respectively.
For example, the SP-A2 1A2 haplotype referred to in Fig. 3 consists of SNPs encoding amino acids 9, 91,
140, and 223 (AA9 C/AA91 G/AA140 C/AA223 C) [11]. The SP-D locus is in physical proximity with
the SP-A locus [23] and in Fig. 3 the co-transmission of the SP-D SNPs with the 1A2 haplotype are shown.
corporated onto the DNA strand. As each nucleotide
is dispensed, the complementary strand is synthesized
and its signals generate a PyrogramTM. Each light sig-
nal corresponds to a single peak in the pyrogram. Pyro-
grams are scored by pattern-recognition software that
compares the predicted SNP pattern (histogram) to the
observed pattern (pyrogram) (Pyrosequencing AB, Up-
psala, Sweden). The ability to quantitate each peak of
the pyrogram provides for numerous advantages. For
example, efficiency of the PCR amplification can be
determined from the peak height. Moreover, specificity
of the template or any non-specific allelic amplification
can be monitored by ensuring appropriate heights of
specific peaks, and lack of incorporation of negative
control nucleotides.
b) Primer design for pyrosequencing: PCR
primers were designed using commercially available
software DNAStar (www.dnastar.com) or Pro-oligo
(www.changbioscience.com) (Table 3). Multiplex
PCR and/or multiplex pyrosequencing primers were
designed to ensure that no homo- and/or heterodimers
occurred, and that there were no false priming sites for
either of the primers on either template. Biotin label
was added to the 5’ end of one of the primers in each
primer pair. The biotin labeling of the primers is cur-
rently carried out by Biomers (www.biomers.com), al-
though other companies have been used in the past. Se-
quencing primers for the pyrosequencing reaction were
designed using the SNP Primer Design Software (tech-
nical support web site of Pyrosequencing AB, Uppsala,
Sweden). These primers anneal directly in front of the
SNP position (or several nucleotides before it) on the
reverse strand of the PCR template to be analyzed. De-
pending on the position of the sequence primer dock-
ing, the dispensation order of nucleotides is determined
by the Pyrosequencing SNP analysis software (Fig. 1).
Nucleotides that are not present in the sequence, can
serve as negative controls, and are dispensed, if pos-
sible, at the beginning of the sequencing reaction as
well as in positions flanking the SNP position (Fig. 1).
The negative control ensures the specificity of the prim-
ing and sequencing reaction. The DNA strand to be
analyzed is elongated through the SNP site.
c) Template preparation and plate set-up for py-
rosequencing: Twenty µl of biotinylated PCR product
was immobilized to streptavidin-Sepharose HP beads
(Amersham Biosciences) and incubated with binding
buffer, 10 mmol/L Tris-HCl, 2 mol/L NaCl, 1 mmol/L
EDTA, 1 mL/L Tween 207 in a 96-weIl microtiter plate
for 10 min at 25◦C with mixing at 1400 rpm. The
96-well plate was then processed through vacuum fil-
tration using the Vacuum Prep Tool (Pyrosequencing
AB), where the bead-bound PCR products were trans-
ferred to the filter at the end of each 96-Filter probe,
and the remaining liquid was removed by vacuum fil-
tration. The Vacuum Prep Tool was passed through
a series of solutions including the denaturation solu-
tion (0.2 mol/L NaOH) that removed non-biotinylated
strands. Sepharose bead-bound biotinylated strands
were retained on the filter and rinsed in washing buffer
(10 mmol/L Tris-acetate, pH 7.6). The vacuum was re-
moved to release the beads from the filter. Bead-bound
single-stranded DNA templates for each SNP were re-
suspended in annealing buffer (20 mMTris-acetate, pH
7.6; 2 mM magnesium acetate) containing 20 pmol of
each respective sequencing primer, in wells of a PSQ
96 plate (Pyrosequencing AB). This mixture was then
heated at 80◦C for 2 min on a compact heat block and
cooled to room temperature for 10 min to facilitate an-
nealing of the Pyrosequencing primers to templates.
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Table 3
Primers used in the study
SNP Gene F # F primer R # R primer Seq # S primer Direction* Simplex/
multiplex
AA19(C/T) SP-A1 1327A cgactggacccagagccatgtc 1328 B-ctggagggccagggtctcctt 1331 cagcctctggtgctg Forward S and M with
AA50
AA50(C/G) SP-A1 1327A cgactggacccagagccatgtc 1328 B-ctggagggccagggtctcctt 1332 cagggacgggagag Forward S and M with
AA19
AA62(A/G) SP-A1 1344 B-tagctccaaccagttgtgggtgac 1345 tgatttccaggaggacatggca 1346 catggcatttctccag Reverse S only
AA133(A/G) SP-A1 1233 B-agtctgcagggctccataatga 28A accctcagtcaggcctacat 1338 ggagaagaccttctctcc Reverse S and M with
AA219
AA219(C/T) SP-A1 1321 aagtacaacacatatgcctat 494 B-tcagaactcacagatggtca 1339 aggggagcccgca Forward S and M with
AA133
AA9(A/C) SP-A2 1327A cgactggacccagagccatgtc 1328 B-ctggagggccagggtctcctt 1333 gccctctggccctca Forward S only
AA91(C/G) SP-A2 1397 tgggaataatgggctgcctg 1398 B-ctgacttcagggtcgctgtg 1399 gagagaagggggag Forward S only
AA140(C/T) SP-A2 1233 B-agtctgcagggctccataatga 28A accctcagtcaggcctacat 1336 tggactgcccattg Reverse S and M with
AA223
AA223(A/C) SP-A2 1321 B-aagtacaacacatatgcctat 494 tcagaactcacagatggtca 1337 tgtgtacatctccacacact Reverse S and M with
AA140
B1580(T/C) SP-B 1313 tcccaggacacgatgaggaag 1390 B-gcaggcaggaggtgagc 1341 tacttccagaacca Forward S only
CA138(A/C) SP-C 1393 B-tccagagagcatccccagtc 1394 gtagtagagcggcacctcgc 1395 tggaagttgtggactttt Reverse S only
CA186(A/G) SP-C 1318 gggctgcacatgggatagaaactc 1319 B-ccctgggatcacacctgctcacc 1320 ggcatggccgtga Forward S only
DA11(C/T) SP-D 1305 gaagcagaaatgaagacctactcc 1301 B-gccactctccactgagctacaca 1302 aagacctactcccacagaa Forward S and M with
AA160
DA160(A/G) SP-D 1306 gaggtgtccctggtgagcgt 1307 B-gtgggtggagggggtgta 1308 gagtccctggaaac Forward S and M with
AA11
All primer sequences are 5’ to 3’. Forward (F) primers are in sense and reverse (R) primers in anti-sense orientation. For forward and reverse
sequencing, the sequencing (Seq) primers are in sense and antisense orientation, respectively. *The forward and reverse direction of the sequencing
assay are noted. In a multiplex reaction two SNPs can be sequenced from a single template (as for AA19/AA50) or from two different templates,
as is the case in all other multiplex reactions showed. Primer numbers are arbitrary laboratory numbers. B stands for the biotin label at the 5’ end
of the primer. S denotes simplex reaction, M denotes multiplex reaction.
The plate was placed into the PSQ HS 96MA System
(Pyrosequencing AB) for analysis. Simplex pyrose-
quencing was performed for genotyping SNPs of all
four genes. Where multiplexing could be achieved, du-
plexing of two SNPs of the same gene was designed,
with the sequencing reaction taking place from either
one or two PCR templates.
2.4. Genotyping of SP SNPs and SP-B microsatellite
markers
Table 2 shows the SNPs studied for all four surfactant
protein genes and SP-B linked microsatellite markers,
and Table 3 the primers used.
I. SP-A analysis
a) SP-A PCR:
i) General: All DNA samples were individually
amplified from non-quantified genomic DNA by PCR
using Taq DNA polymerase (Roche Diagnostics, In-
dianapolis, IN). Two µl of individual DNA samples
were combined with 1 µl of 1.25 mM deoxynucleotide
triphosphate (dNTP) mix,various amounts of each PCR
primer (25 ng/µl to 100 ng/µl), 2.5 µl l0x Buffer 1 and
2.5 µl of l0x Buffer 2 (Roche) in 50 µl overall volume
(this was done for all the SNPs of all four SP genes).
Cycling conditions for SP-A (gene specific reaction)
were as follows: 95◦C for 2 min followed by 35 cycles
of 95◦C for 30’, 58◦C for 1 min, and 72◦C for 1 min.
This was followed by one cycle of 72◦C for 5 min.
PCR profiles for SP-A nested reaction were as follows:
95◦C for 2 min followed by 35 cycles of 95◦C for 30’,
60◦C for 30’, and 72◦C for 30’. This was followed
by one cycle of 72◦C for 5 min. An aliquot of the
PCR reaction was run on 8% PAGE gel to verify size
and quantity of PCR product, and most importantly to
ensure the presence of a single PCR band in simplex
PCR or two bands in multiplex PCR. The outline of the
SP-A SNP genotyping approach is presented in Fig. 2.
ii) SP-A1: primer pair 1327A/293 was used to gener-
ate a 549 bp long PCR product, which was used as tem-
plate for nested reactions for AA19, AA50, and AA62.
Due to the spatial proximity of AA19 and AA50, these
SNPs were amplified on the single DNA strand of a 187
bases product generated with 1327A/1328 primer pair.
The 549 bp PCR product was also used as a template in
a nested reaction with primers 1344/1345 to generate a
fragment for analysis of AA62. The second gene spe-
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SP- A1
AA19 AA50 29GS
3
1331            1332
1346
SP- A2
AA9
1327A
29
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2
1327A
1333
1328 
SP- A11233
1233 AA133
5 
GS
1338
1339
AA21
9
1321
28A
SP- A2
AA91
1398
3
GS
1233 AA140
28A1336
1337
AA2231321
5 3AA133 AA140 AA219 AA223AA91AA62AA50AA19AA9
1399
1327A
1327A
1344
1397
803
1345 
1328 
494 
494 
PCR fragment encoding amino acids 1-85 PCR fragment encoding amino acids 86-248
Fig. 2. Schematic representation of SP-A PCR and pyrosequencing for PCR fragments encoding amino acids 1-248: Forward and reverse
primers are presented with thin arrows, and GS (gene specific) stands for gene specific primers (SP-A1 or SP-A2 specific). Grey circles represent
biotin label at the primer end. Sequencing primers are presented with thick arrows.
cific fragment of SP-A1 was amplified using primers
1233/5 to generate a 422 bp fragment. Two nested
reactions were performed on this template; a 200 bp
fragment for AA133 with primer pair 1233/28A and a
209 bp fragment for AA219 with primer pair 1321/494.
iii) SP-A2: A 541 bp long PCR product was am-
plified with primer pair 1327A/292 and used as tem-
plate in nested PCR with primer pair 1327A/1328 to
generate a 186 bp fragment for AA9 analysis. The
second gene specific fragment of SP-A2 was amplified
using primers 803/3 to generate a 1700 bp fragment.
This fragment was used as a template in three nested
PCR reactions: 1) with primers 1397/1398 to generate
a 129 bp fragment for AA91 pyrosequencing, 2) with
primers 1233/28A to generate a 200 bp fragment for
AA140 pyrosequencing, 3) with primers 1321/494 to
generate a 223 bp fragment for AA223 pyrosequencing.
Due to the cost of biotinylated primers, the objective
was to have as many as possible overlapping primers
in the nested reactions for the two genes. Therefore,
the same primer pairs were used for AA9, AA19, and
AA50; for AA133 and AA140; and for AA223 and
AA219.
b) SP-A pyrosequencing: All pyrosequencing re-
actions were first performed in simplex, where a single
SNP was analyzed at a time, using 20 µl of the PCR
reaction. Where possible, cost effective multiplex py-
rosequencing assays were designed. For SP-A1, AA19
and AA50 were sequenced in duplex using 20 µl of a
singular template and both SNPs were analyzed in for-
ward assays. A reverse AA133 assay was performed
in multiplex with a forward AA219 assay, using 15 µl
of AA133 PCR template and 25 µl of AA219 template,
to achieve optimal intensity in the ratio of the signal
from each template. For SP-A2, 20 µl of AA140 PCR
product was pyrosequenced in multiplex with 20 µl of
AA223 PCR product. Both SNPs were pyrosequenced
either in simplex or multiplex assays as schematically
presented in the Fig. 1. Overall, complete genotyping
of both SP-A genes requires 12 PCR reactions and 6
pyrosequencing reactions.
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c) SP-A molecular haplotypes: The advantage
of being able to pyrosequence AA19 and AA50 on
a single DNA strand, allows for direct molecular
haplotyping of these two SNPs. In SP-A1, the
AA19(C)AA50(G) haplotype was not observed in 152
individual DNA samples genotyped by pyrosequencing
and in 100 samples genotyped by PCR-cRFLP [11].
FBAT was used to estimate frequencies of SP-A1,
AA19(C/T)AA50(C/G), haplotypes in 1534 individu-
als. The frequency of AA19(T)AA50(G) haplotype
was 0.532, the frequency of AA19(T)AA50(C) was
0.383, the frequency of AA19(C)AA50(C) was 0.083,
while the frequency of AA19(C)AA50(G) was 0.001.
These observations together indicate that the SP-A1
haplotype AA19(C)AA50(G) is extremely rare (ap-
proximately 1 in 1000).
II. SP-B analysis:
a) SP-B SNP genotyping: Genotyping for the SP-B
SNPs B-18(A/C), B1013(A/C), and B9306(A/G) was
performed for all samples using the PCR based con-
verted Restriction Fragment Length Polymorphisms
(cRFLP) method, as described before [36,51]. Geno-
typing for SP-B marker B1580(C/T) was done by both
PCR-cRFLP and pyrosequencing. PCR for marker
B1580(T/C) was performed using oligos 1313/1390
and cycling conditions were as follows: 95◦C for 2 min
followed by 35 cycles of 95◦C for 30’, 58◦C for 1 min,
and 72◦C for 1 min. This was followed by one cycle
of 72◦C for 5 min. An aliquot of the PCR reaction
was run on 8% PAGE gel to verify size and quantity
of PCR product, and most importantly to ensure the
presence of a single PCR band. Pyrosequencing of the
PCR product was done using sequencing with primer
1341.
b) Microsatellite genotyping was performed for
SP-B-linked microsatellites, AAGG, D2S22 32, and
D2S388, as described previously [31].
III. SP-C analysis:
Genotyping for SP-C markers CA138(A/C) and CA186
(A/G) was performed as previously described [51] us-
ing the PCR-cRFLP method.
IV. SP-D analysis:
Simplex or multiplex PCR for DA11 and DA160 of
SP-D was performed using primer pair 1301/1305 for
DA11 and primer pair 1306/1307 for DA160. PCR
profiles for SP-D both simplex and multiplex reaction
were as follows: 95◦C for 2 min followed by 35 cycles
of 95◦C for 30’, 59◦C for 30’, and 72◦C for 30’. This
was followed by one cycle of 72◦C for 5 min. An
aliquot of the PCR reaction was run on 8% PAGE gel
to verify size and quantity of PCR product, and most
importantly to ensure the presence of a single PCR
band in simplex PCR or two bands in multiplex PCR.
These SNPs were pyrosequenced either in simplex or
multiplex forward assays using oligos 1301 and 1308,
respectively.
2.5. Statistical analysis
PedCheck program was used to check the compati-
bility of genotypes at each marker locus within fami-
lies, prior to analysis [44]. Marker loci with incompat-
ible parental and offspring genotypes, were treated as
missing in those families. Association between alleles
of surfactant protein genes and BPD was tested using
the Transmission Disequilibrium Test (TDT) [56] and
Family Based Association Test FBAT [24,34,47].
TDT analysis was performed using GENEHUN-
TER [33] (Whitehead Institute for Biomedical Re-
search, MIT) to determine, transmission of individ-
ual surfactant protein (SP-A, SP-B, SP-C, and SP-D)
marker alleles and SP-B-linked microsatellite marker
alleles from heterozygous parents to affected offspring,
and also to test for transmission of SP-B haplotypes
of two, three, and four marker loci. In this analysis
it is sufficient for only one parent to be heterozygous
for the marker in order for a family to be considered
informative and thus used in the study. Extended TDT
(ETDT) analysis was performed to assess linkage of a
multi-allele locus to the disease locus [7,52].
FBAT analysis was performed using the online pro-
gram, http://www.biostat.harvard.edu/˜fbat/fbat.htm.
Bi-allelic FBAT analysis was performed for SP SNP
markers and selected microsatellites [24,34,47]. Multi-
allelic analysis, where association of the entire lo-
cus with disease is examined, was also performed for
marker loci with multiple alleles [24]. All of the FBAT
analyses were performed assuming an additive model.
The minimum size [minsize] of FBAT analyses was set
to 4 indicating that the test statistic was not computed
when the number of informative families available was
fewer than 4. Informative families refer to families with
non-zero contribution to the FBAT statistic. For each
FBAT marker, the Z-statistic and the corresponding p
value are listed. A significant p value and a positive
Z-statistic are indicative of a susceptibility marker al-
lele for disease, while a significant p value and a nega-
tive Z-statistic is indicative of a protective marker allele
for disease. TDT and FBAT analyses were performed
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for the following groups: BPD 28D, BPD 36W, and
BPD 28D/36W.
Stratified FBAT analyses were also performed within
each group based on baby’s steroid treatment, mother’s
steroid treatment, and baby’s surfactant therapy. Hap-
lotype analyses were performed using the FBAT pro-
gram, which implements an EM based algorithm [25].
EM algorithm is a general method of finding the
maximum-likelihood estimate of the parameters of an
underlying distribution from a given data set when the
data set is incomplete or has missing values. For single
marker analysis, FBAT and TDT gave the same results,
although some differences were observed in the haplo-
type analysis, perhaps due to subtle differences in the
assumptions each method makes (see discussion). For
both TDT and FBAT analysis, significant results were
noted when p was smaller or approaching 0.01. Results
were not corrected for multiple comparisons.
Inferred haplotype reconstruction was performed us-
ing FBAT, where the most likely haplotypes were as-
signed for each individual infant. FBAT compares the
distribution of test statistics using the conditional off-
spring genotype distribution under the null hypothe-
sis [25]. The offspring genotype probabilities were
computed given the parental mating type.
3. Results
We examined transmission of individual SNPs for
all five surfactant protein genes and SP-B-linked mi-
crosatellites markers (Table 2).
I. Family-based allele association analysis:
a) SP SNPs marker alleles and SP-B-linked mi-
crosatellites: Tables 4A and 4B, summarize the re-
sults of TDT and bi-allelic FBAT analysis, of SP-B
and SP-B-linked markers, respectively. In both TDT
and FBAT analysis, allele 6 of the AAGG marker was
found to be transmitted more frequently to the affected
offspring in BPD 28D/36W (p = 0.011, Table 4). The
SP-B marker locus B-18(A/C) was found to be asso-
ciated with BPD 36W group by both TDT and FBAT
(p = 0.018), where the A allele was associated with
protection and the C allele with susceptibility to dis-
ease. No significant associations were found for in-
dividual allelic variants of SP-A, SP-C, and SP-D by
either TDT or FBAT.
b) SP marker alleles stratified for pre-natal/neo-
natal treatments: Stratified bi-allelic FBAT analysis
was performed to investigate the possible effect of pre-
natal/neo-natal treatments on the outcome of BPD ba-
bies. Analyses were stratified according to the three
co-variates: 1) lack or presence of pre-natal steroids,
2) lack or presence of post-natal steroids, and 3) lack
or presence of surfactant therapy. Of significance is
that in the combined BPD group and BPD 28D, allele
4 of the D2S388 marker locus was associated with pro-
tection from disease in babies that did not receive pre-
natal steroid treatment (p = 0.01). When the effect
of post-natal steroids was investigated, allele 7 of the
AAGG marker was associated with a protective effect
(in BPD 28D, p = 0.014) while allele AAGG 6 (in the
combined BPD group, p = 0.019) and B-18 C (in the
BPD 36W, p = 0.018) was associated with susceptibil-
ity to disease in babies treated with post-natal steroids.
Allele AAGG 6 was also found to be related to sus-
ceptibility in the combined BPD group that received
surfactant therapy (p = 0.008).
These results are in concordance with those of non-
stratified analysis, as would be expected, since the ma-
jority of infants have received post-natal steroid treat-
ment. On the other hand, in the smaller subgroup of
BPD 28D (babies that did not receive post-natal surfac-
tant therapy) allele 4 of the D2S388 marker was associ-
ated with a protective effect from disease (p = 0.008).
The functional significance of these associations re-
mains to be determined, particularly since the sample
number of families under study is small for all, except
for BPD at 28 days post-natal steroid treatment group.
II. Family-based haplotype association analysis:
a) SP-A and SP-D SNP haplotypes: Figure 3 de-
picts the findings of association between haplotypes of
SP-A2 and SP-D genes and disease groups by TDT.
In the BPD 28D group the DA160(G)SP-A2(1A2)
(p = 0.005) and the DA11(C)DA160(G)SP-A2(1A2)
(p = 0.014) haplotypes of SP-D/SP-A2 were not trans-
mitted to the affected child. Therefore these haplo-
types may act as protective factors in the BPD 28D
subgroup. No significant associations were found for
SP-A and SP-D haplotypes in the BPD 36W subgroup.
Neither ETDT, nor bi and multi-allelic FBAT analysis
showed any significant association between individual
SP-A alleles and BPD disease subgroups.
b) Haplotype analysis of SP-B SNP marker alleles
and SP-B-linked microsatellite markers: Haplotype
analyses were performed by both TDT (generated by
Genehunter) and FBAT for two, three, and four markers
at the time, and by FBAT for five,six, and seven markers
at the time. The results of TDT and FBAT analyses are
listed in Tables 5A and 5B, respectively. Of note is that
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Table 4A
TDT analysis of SP-B marker alleles
Disease group Markers allele # of # of non- X2 p-value effect
transmitted alleles transmitted alleles
BPD 36W=Y B-18(A/C) C 14 4 5.56 0.0180 susceptibility
BPD 28D/36W AAGG 6 9 1 6.4 0.0114 susceptibility
Table 4B
Bi-allelic FBAT analysis of SP-B marker alleles
Disease group marker allele Family # Z p value minsize* effect
BPD 36W=Y B-18(A/C) C 11 2.357 0.0180 10 susceptibility
BPD 28D/36W AAGG 6 7 2.53 0.0114 10 susceptibility
Disease groups: 1) =Ydenotes BPD at 36 weeks post-conceptual age; 2) denotes combined group of
BPD at 28 days and BPD at 36 weeks post-conceptual age;
*Minsize denotes the minimum number of informative families necessary to compute the test statistics.
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Fig. 3. TDT analysis of SP-A haplotypes: Significant haplotypes for BPD 28D/36W and BPD 36W are presented where p values approach 0.01.
All 60 families were used in the analyses (n = 52 for BPD 28D; n = 19 for BPD 36W).
in most cases individual alleles found to be associated
with either protection or susceptibility from disease in
Table 4, were also found to form haplotypes that were
associated with the same overall effect.
SP-B-linked microsatellite markers were found in
several disease associated haplotypes. The frequency
of transmission of haplotype AAGG 6/B-18 C to ba-
bies in the BPD 28D/36W group was increased by TDT
(p = 0.008), as well as the AAGG 6/B-18 C/B1013 A
haplotype (p = 0.014). Moreover, the frequency of
transmission of the AAGG 7-containing haplotypes to
babies in all three subgroups was decreased by TDT
(p = 0.02), and the D2S2232 1/AAGG 7 haplotype
was found less frequently in BPD 28D/36W group
(p = 0.014).
Figure 4 provides a schematic presentation of hap-
lotypes among different disease subgroups by the
two different tests, TDT and FBAT. Presence of
AAGG 6 allele in haplotypes was consistently asso-
ciated with susceptibility to disease, while the pres-
ence of AAGG 7 allele was associated with a pro-
tective effect from disease. Although, AAGG 3 al-
lele was found in three susceptibility haplotype com-
binations, this allele may not be informative as the
AAGG 6 and AAGG 7 alleles may be, because it was
also found in protection associated haplotypes (not
shown: p  0.05). The AAGG 3 containing haplo-
types are, D2S2232 2/AAGG 3 found to associate with
BPD 28D group by TDT, D2S388 5/D2S2232 2/AAG
G 3 found to associate with both the BPD 28D and
BPD 28D/36W by FBAT (in both p = 0.01), and
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D2S388 5/D2S2232 2/AAGG 3/B-18 A found to as-
sociate with the BPD 28D/36W group by FBAT (p =
0.01).
SP-B SNP marker haplotype, B-18 C/B1013 A was
associated with susceptibility by both TDT and FBAT
analysis in BPD 36W (p = 0.002 and p = 0.014,
respectively) whereas B-18 C/B1013 A/B1580 T and
B-18 C/B1013 A/B1580 T/B9306 A haplotypes were
associated with susceptibility in the same group only
by TDT.
Overall, both individual allele and haplotype anal-
ysis of SP-B markers indicate an association of the
microsatellite marker AAGG 6 allele with susceptibil-
ity to disease in infants affected with BPD 28D/36W.
SNP marker B-18(A/C) alleles were associated with
the more severely affected babies, where the C allele
associated with susceptibility and the A allele with pro-
tection from BPD 36W.
4. Discussion
BPD is a multifactorial disease of preterm infants
where multiple risk factors contribute to permanent
pathophysiologic changes. Numerous genes required
for neonatal lung adaptation are likely to be involved
in the etiology of this disease. Since surfactant pro-
teins are essential for normal lung function and play a
role in both gas exchange and innate immune mecha-
nisms of the lung, they are likely to play a role in the
pathogenesis of BPD. Susceptibility to RDS, the com-
mon precursor of BPD has been shown to be linked
to surfactant proteins, and SP-A in particular [16–18,
20,21,48]. Recently, in a case-control study, an SP-B
intron 4 deletion variant was identified as a risk factor
in BPD [50]. In order to avoid spurious associations
secondary to population stratification, characteristic of
case-control studies, we performed family based asso-
ciation analyses. Such analyses are not confounded
by population characteristics and provide a more pow-
erful analysis even in small sample sizes [54]. The
data from TDT and FBAT (using two powerful family
based association tests) revealed, a) association of SP-
B with susceptibility to BPD 36W; and b) association
of the microsatellite marker AAGG 6 with susceptibil-
ity in the BPD 28D/36W group; c) Ten susceptibility
and one protective haplotypes for SP-B and SP-linked
microsatellite markers were detected for all three sub-
groups (BPD 28D, BPD 36W, and BPD 28D/36W); d)
TDT analysis revealed two SP-A/SP-D susceptibility
haplotypes for BPD 28D.
Of the 71 infants in the study, 52 had the less se-
vere BPD 28D, while 19 infants were affected with the
more severe BPD 36W. Although the sample size in
BPD 36W may be small, the use of the family based as-
sociation approach may mitigate the margin of error due
to small sample size [54]. However, it should be noted
that the majority of observations in the BPD 28D/36W
group overlap with those for the BPD 28D sub-group,
perhaps due to the predominance of the sample size of
this group.
The SP-A2/SP-D haplotypes found to associate with
protection from BPD 28D have not been previously
studied. The lack of association with SP-A in the
Finnish BPD study is most likely due to the fact that
their study group consisted of more severely affected
babies (86 infants had BPD at 36 weeks, and 21 had
BPD at 28 days). The inflammatory components that
appear to be at work in the early stages of the disease
could be modulated by SP-A and SP-D [28], which may
be consistent with their immune related functions [46].
Although it is unknown how the SP-A2(1A2)/SP-D
haplotypes may protect from BPD, we speculate that
this protection is likely due to adequate levels of SP-A
and/or SP-D at a critical developmental stage of the
lung. In-vitro studies have shown genotype-dependent
levels of SP-A mRNA [32] as well as differences among
SP-A2 variants in 3’UTR mediated expression [59]. It
is unlikely that the association reflects functional dif-
ferences, because the SP-A2, 1A2 variant is identical
in the amino acid sequence of the mature protein with
several other SP-A2 variants [11]. With regards to SP-
D, the DA11(C/T) SNP was recently identified to af-
fect oligomerization, function, and serum concentra-
tions of the protein [35]. Individuals homozygous for
the DA11(C/C) variant were found to have significantly
lower SP-D serum levels than the DA11(T/T) homozy-
gous individuals. Polymorphisms of SP-A were not
investigated in this study [35].
SP-B SNP variant alleles and/or haplotypes on the
other hand were only associated with the BPD 36W.
Specifically, the C variant of the B-18(A/C) polymor-
phism within the 5’UTR of SP-B was found, either
alone or in various haplotypes, to associate with sus-
ceptibility to BPD 36W by both TDT and bi- and
multi-allelic FBAT. The finding of the SP-B intron 4
polymorphism association with BPD in a Finish study
group [50], along with the present findings support a
role of SP-B in BPD pathogenesis. Recently, a dual
role for SP-B, as a protein essential for surfactant func-
tion and as an anti-inflammatory mediator, has been
proposed that could explain involvement of this pro-
J. Pavlovic et al. / Surfactant proteins in BPD 287
B. Susceptibility to disease
A. Protection from disease
1                                     7
1  (A )
7 1  (A )                   2  (C )
7 2  (C )                  1  (A )
BPD_28D/36W
BPD_28D
BPD_36W
2  (C ) 1  (A ) 4  (T)                 1  (A ) 
6 2  (C) 1  (A )
6 2  (C)
6
BPD_36W
BPD_28D/36W
BPD_28D
TDT/FBAT
+/+
+/-
+/-
+/+
5 2 3 1  (A )
2  (C )     
5 2 3  
2  (C ) 1  (A) 
2  (C ) 1  (A ) 4  (T)  
5 2 3  
+/-
-/+
-/+
+/+
+/+
+/+
+/-
+/-
+/+
+/+
C T
D2S388 D2S2232 AAGG -18 (A/C)
1013(A/C) 1580(C/T) 9306(A/G)
SP-B
2 3  
-/+
Fig. 4. Schematic presentation of susceptibility and protection haplotypes: Significant findings by both TDT and FBAT are presented in the Figure.
A schematic representation of four SP-B SNPs B 18(A/C), B1013(A/C), B1580(C/T), B9306(A/G), and SP-B-linked microsatellite markers, is
shown in the middle of the Figure. The centromeric (C) and telomeric (T) orientation of this DNA segment is also noted. The microsatellite marker
AAGG is 27 kb from SP-B [31]. Markers D2S2232 and D2S388 are 120 kb and 195 kb from SP-B (according to the current version CH 2 map
http://www.ensembl.org:80/Homo sapiens/geneview?gene=ENSG00000168878). Above the schematic presentation, protection haplotypes are
shown (Table 5A) and below the schematic presentation susceptibility haplotypes are noted (Table 5B). The nucleotide for each SNP is also noted
by a number: A = 1, C = 2, G = 3, and T = 4. For example in BPD 36W susceptibility haplotype B 18 C/B1013 A/B1580 T/B9306 A is
also noted as haplotype 2/1/4/1. The alleles for each microsatellite marker locus have been defined previously [31] and are noted by numbers 1, 2,
3, etc. The haplotypes noted here are described in detail in Tables 4 and 5. Only significant findings where p value approaches 0.01 are presented.
The plus (+) sign in the left hand column denotes a haplotype that was found by either TDT or FBAT, while the minus (−) sign denotes that a
particular haplotype was not found to have a significant p value by either TDT or FBAT.
tein in BPD [13] at multiple levels. Regulatory roles
in SP-B gene expression of SP-B that B-18(A/C) SNP
and intron 4 variants [50] may have can only be spec-
ulated. Inadequate levels of SP-B may contribute to
the progression of BPD especially in the later stages of
the disease progression. Infants that require continued
ventilatory support, as in BPD, experience transient
episodes of surfactant dysfunction that are associated
with deficiency in SP-B [43].
Mulltiallelic SP-B-linked microsatellite markers
were also used to increase resolution in the definition
of the genetic background of BPD subgroups. Of the
three markers studied, AAGG and specifically allele
AAGG 6 was found to associate with BPD 28D/36W.
This microsatellite marker is located 26 kb upstream
from SP-B, and allele 6 consists of 24 AAGG re-
peats [31]. No difference in transcription factor bind-
ing among the alleles of AAGG was found by current
bioinformatics techniques (JASPAR transcription fac-
tor data base). It is currently unknown whether this
marker imparts a direct functional effect on SP-B in
relation to BPD, or whether it is linked to another gene
and/or to a functional genetic variant(s) that is located
in, or close to the SP-B gene.
To identify genes between the microsatellite marker
AAGG locus and the SP-B SNPs an ensemble gene
search (www.ensembl.org) was conducted. The only
known gene located within this region is granulysin, a T
cell activation gene. Although granulysin has not been
implicated in the pathogenesis of BPD, this gene plays
a role in immunity against intracellular pathogens, and
may therefore be involved in the modulation of inflam-
matory responses in BPD [45]. However, the disease
locus does not have to be limited to this region, and
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Table 5A
TDT analysis of SP-B marker haplotypes
Disease group Markers haplotype # # non- X2 p-value effect
transmitted transmitted
BPD 28D/36W AAGG-B-18(A/C) 6 2 7 0 7 0.008 susceptibility
BPD 28D/36W D2S2232-AAGG 1 7 0 6 6 0.014 protection
BPD 28D* D2S2232-AAGG 2 3 13 3 6.25 0.013 susceptibility
BPD 36W=Y B-18(A/C)-B1013(A/C) 2 1 10 0 10 0.002 susceptibility
BPD 28D* AAGG-B-18(A/C)-B1013(A/C) 7 2 1 8 21 5.83 0.016 protection
BPD 28D/36W AAGG-B-18(A/C)-B1013(A/C) 6 2 1 6 0 6 0.014 susceptibility
BPD 28D/36W AAGG-B-18(A/C)-B1013(A/C) 7 1 2 1 8 5.44 0.019 protection
BPD 36W B-18(A/C)-B1013(A/C)-B1580(C/T) 2 1 4 6 0 6 0.014 susceptibility
BPD 36W B-18(A/C)-B1013(A/C)-B1580(C/T)- 2 1 4 1 6 0 6 0.014 susceptibility
B9306(A/G)
Disease groups: 1) *Denotes BPD at 28 days; 2) =Y denotes BPD at 36 weeks post-conceptual age; 3) denotes combined group of BPD at 28
days and BPD at 36 weeks post-conceptual age;
For B-18(A/C), B1013(A/C), and B1580(C/T): 1 denotes A variant, 2 (C variant), and 4 (T variant).
# transmitted and # non-transmitted denotes the # of haplotypes.
Table 5B
FBAT analysis of SP-B marker haplotypes
Disease group marker allele Family # Z p value minsize* effect
BPD 36W=Y B-18(A/C)-B-1013(A/C) 2 1 7 2.554 0.014 4 susceptibility
BPD 28D* D2S388-D2S2232-AAGG 5 2 3 5 2.558 0.010 4 susceptibility
BPD 28D/36W D2S2232-AAGG 1 7 7 −2.376 0.017 4 protection
BPD 28D/36W AAGG-B-18(A/C) 6 2 6 2.333 0.019 4 susceptibility
BPD 28D/36W AAGG-B-18(A/C)-B1013(A/C) 6 2 1 6 2.333 0.019 4 susceptibility
BPD 28D/36W D2S388-D2S2232-AAGG 5 2 3 5 2.558 0.010 4 susceptibility
BPD 28D/36W D2S388-D2S2232-AAGG-B-18(A/C) 5 2 3 1 5 2.558 0.010 4 susceptibility
Disease groups: 1) *Denotes BPD at 28 days; 2) =Y denotes BPD at 36 weeks post-conceptual age; 3) denotes combined group of BPD
at 28 days and BPD at 36 weeks post-conceptual age;
For B-18(A/C) 1 denotes A variant and 2 (C variant).
*Minsize denotes the minimum number of informative families necessary to compute the test statistics.
may in fact be much further upstream or downstream.
Although association data may identify and implicate
genes in the clinical course of a disease, functional
analysis of variants of interest should be conducted to
better understand their role in BPD pathogenesis.
Multilocus haplotype association analyses are ad-
vantageous because they provide a stronger power of
association than the single nucleotide methods [66].
The results from these analyses confirmed and ex-
tended on the trends seen by individual SNP analy-
sis. Combinations of B-18 C, B1013 A and B1580 T
were found in susceptibility haplotypes by both
TDT and FBAT. Moreover, significant three marker
linkage disequilibrium for B-18(A/C), B1013(A/C),
and B1580(C/T) has been reported in several pop-
ulations [37]. In the Greek population the fre-
quency of the B-18 C/B1013 A/B1580 T and B-
18 A/B1013 C/B1580 C haplotypes of these three
marker loci is the same (0.274) [37]. Therefore, asso-
ciation of the CAT haplotype of these marker loci with
susceptibility to BPD in this study is not an artifact
of the overall population characteristic, but it may be
rather disease related.
Although FBAT and TDT analyses identified similar
alleles and/or haplotypes associated with BPD, differ-
ent findings were also observed between these two anal-
yses. For example, FBAT revealed haplotypes with ad-
ditional upstream loci (D2S388 5/D2S2232 2/AAGG
3 and D2S388 5/D2S2232 2/AAGG 3/B-18 A) for
BPD 28D and BPD28D/36W. The basis for the ob-
served differences is currently unknown, but it may
be due to differences in approach and/or the under-
lying assumptions of the two tests (TDT and FBAT).
Haplotype TDT uses the maximum likelihood ap-
proach based on the Lander-Green hidden-Markov-
model (HMM) [33], while the FBAT uses a weighted
conditional approach [25]. Therefore, the differences
in results are more likely to occur for low frequency
haplotypes. Moreover, haplotype FBAT assumes no re-
combination among the marker loci [25] and haplotype
TDT assumes no linkage disequilibrium [33]. Recent
studies have used these two tests in complement for
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either single nucleotide polymorphism analysis [5,40,
64] or haplotype analysis [8]. However, the partial dis-
crepancies observed in the results by these two different
family based association tests in these studies as well as
the results presented in this study, point to the need for
future studies to compare different analytical methods
in parallel. Such efforts could identify differences in
approach and assumption, understand the implications
of such differences and clearly define advantages and
disadvantages of each approach.
Due to the presumed overlap between BPD and RDS,
it was hypothesized that similar genetic association
findings would be seen in these two diseases [17,22]. It
was, therefore, surprising that the B1580 T variant was
found in the susceptibility haplotypes in the present
study. This SNP codes for the non-glycosylated Ile
(A TT) variant [58]. This variant has been associated
with decreased risk of RDS in blacks in the presence of
the SP-A1 allele (6A3) [17], whereas the glycosylated
Thr (ACT) variant has been shown to associate with
susceptibility to RDS especially in the first born and
male infant in a study of prematurely born twins [17,
41]. However, this is consistent with previous obser-
vations where factors that may protect from RDS, in-
crease risk for BPD. For example, prenatal inflamma-
tion (chorioamnionitis) and increased post-natal lung
inflammation associate with a decreased incidence of
RDS among preterm babies, but these are associated
with an increased risk for chronic lung injury following
preterm delivery [60].
In summary, factors involved in predisposing infants
to develop BPD following RDS are likely complex and
presumably involve several loci with small effects, ef-
fectively making the traditional genetic studies diffi-
cult. In the present study, using two different family
based association tests, we show that the SP-A/SP-D
locus associates with BPD 28D, and the SP-B and SP-
B-linked microsatellite marker loci with BPD 36W and
BPD 28D/36W. However, larger sample size studies
with various BPD subgroups are needed to extend these
results and enable localization and characterization of
genetic factors.
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